Current status of HIV therapy: II. Opportunistic diseases.

Infections and malignancies account for most deaths in patients with AIDS and will continue to do so as long as HIV-induced immunosuppression is progressive and irreversible. Co-trimoxazole has emerged as the preferred agent for prevention of Pneumocystis carinii pneumonia. As appropriate broad-spectrum agents are developed, multiple opportunistic pathogen prophylaxis could become effective.

[1]  M. Saag,et al.  A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. , 1992, The New England journal of medicine.

[2]  MD Carol A. Kemper,et al.  Treatment of Mycobacterium avium Complex Bacteremia in AIDS with a Four-Drug Oral Regimen , 1992, Annals of Internal Medicine.

[3]  J. Feinberg,et al.  New developments in the treatment of Pneumocystis carinii pneumonia. , 1992, Chest.

[4]  M. Saag,et al.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[5]  J. Montaner,et al.  Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A randomized, placebo-controlled study. , 1991, Annals of internal medicine.

[6]  D. Richman,et al.  A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. , 1990, The New England journal of medicine.

[7]  D. Northfelt,et al.  Extrapulmonary Pneumocystosis: Clinical Features in Human Immunodeficiency Virus Infection , 1990, Medicine.

[8]  P. Volberding,et al.  Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. , 1990, The New England journal of medicine.

[9]  N. Benowitz,et al.  Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. , 1990, The New England journal of medicine.

[10]  J. McCutchan,et al.  Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. , 1990, Annals of internal medicine.

[11]  H. Masur,et al.  AIDS-related infections. , 1990, Scientific American.

[12]  P. Meier,et al.  Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. , 1990, The New England journal of medicine.

[13]  S. Follansbee,et al.  Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. , 1990, The Journal of infectious diseases.

[14]  L. Grayson,et al.  Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. , 1990, The Journal of infectious diseases.

[15]  J. Carlin,et al.  Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. , 1991, Journal of acquired immune deficiency syndromes.

[16]  Levin Am,et al.  HIV-related neoplastic disease: 1991. , 1991 .

[17]  J. Mills,et al.  Treatment of opportunistic infections. , 1990, AIDS.